Cargando…

Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020

BACKGROUND: Differentiating between type 1 diabetes (T1D) and type 2 diabetes (T2D) can be difficult in adults. The aim of this study was to determine the frequency of diagnostic reclassification from T2D to T1D, the characteristics of the patients and the impact on the management of the disease. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez Escobedo, Raúl, Lambert, Carmen, Morales Sánchez, Paula, Delgado Álvarez, Elías, Menéndez Torre, Edelmiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155490/
https://www.ncbi.nlm.nih.gov/pubmed/37138364
http://dx.doi.org/10.1186/s13098-023-01069-y
_version_ 1785036339682476032
author Rodríguez Escobedo, Raúl
Lambert, Carmen
Morales Sánchez, Paula
Delgado Álvarez, Elías
Menéndez Torre, Edelmiro
author_facet Rodríguez Escobedo, Raúl
Lambert, Carmen
Morales Sánchez, Paula
Delgado Álvarez, Elías
Menéndez Torre, Edelmiro
author_sort Rodríguez Escobedo, Raúl
collection PubMed
description BACKGROUND: Differentiating between type 1 diabetes (T1D) and type 2 diabetes (T2D) can be difficult in adults. The aim of this study was to determine the frequency of diagnostic reclassification from T2D to T1D, the characteristics of the patients and the impact on the management of the disease. METHODS: Observational and descriptive study including patients diagnosed with T1D in Asturias (Spain) between 2011 and 2020 who had been considered as T2D for at least 12 months. RESULTS: A total of 205 patients were included, representing 45.3% of those diagnosed with T1D over 30 years of age. Median time of evolution as T2D was 7,8 years. The age was 59.1 ± 12.9 years. BMI was > 25 kg/m(2) in 46.8% of patients. HbA1c was 9.1 ± 2.1%, 77 ± 22 mmol/mol, and 56.5% were using insulin. Pancreatic antibodies were present in 95.5%, the most frequent being GAD, 82.6%. At 6 months, basal insulin use increased from 46.9 to 86.3%, and HbA1c decreased, 9.2 ± 2.0%vs7.7 ± 1.2%, 77 ± 22vs60 ± 13 mmol/mol; p < 0.0001. CONCLUSIONS: Diagnosis as T2D in patients with T1D in adults is common. Age, BMI, insulin use and other clinical features are not definitely discriminatory. GAD is the antibody of choice in case of diagnostic suspect. Reclassification has important implications for metabolic control.
format Online
Article
Text
id pubmed-10155490
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101554902023-05-04 Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020 Rodríguez Escobedo, Raúl Lambert, Carmen Morales Sánchez, Paula Delgado Álvarez, Elías Menéndez Torre, Edelmiro Diabetol Metab Syndr Research BACKGROUND: Differentiating between type 1 diabetes (T1D) and type 2 diabetes (T2D) can be difficult in adults. The aim of this study was to determine the frequency of diagnostic reclassification from T2D to T1D, the characteristics of the patients and the impact on the management of the disease. METHODS: Observational and descriptive study including patients diagnosed with T1D in Asturias (Spain) between 2011 and 2020 who had been considered as T2D for at least 12 months. RESULTS: A total of 205 patients were included, representing 45.3% of those diagnosed with T1D over 30 years of age. Median time of evolution as T2D was 7,8 years. The age was 59.1 ± 12.9 years. BMI was > 25 kg/m(2) in 46.8% of patients. HbA1c was 9.1 ± 2.1%, 77 ± 22 mmol/mol, and 56.5% were using insulin. Pancreatic antibodies were present in 95.5%, the most frequent being GAD, 82.6%. At 6 months, basal insulin use increased from 46.9 to 86.3%, and HbA1c decreased, 9.2 ± 2.0%vs7.7 ± 1.2%, 77 ± 22vs60 ± 13 mmol/mol; p < 0.0001. CONCLUSIONS: Diagnosis as T2D in patients with T1D in adults is common. Age, BMI, insulin use and other clinical features are not definitely discriminatory. GAD is the antibody of choice in case of diagnostic suspect. Reclassification has important implications for metabolic control. BioMed Central 2023-05-03 /pmc/articles/PMC10155490/ /pubmed/37138364 http://dx.doi.org/10.1186/s13098-023-01069-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rodríguez Escobedo, Raúl
Lambert, Carmen
Morales Sánchez, Paula
Delgado Álvarez, Elías
Menéndez Torre, Edelmiro
Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title_full Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title_fullStr Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title_full_unstemmed Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title_short Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
title_sort reclassification of type 2 diabetes to type 1 diabetes in asturias (spain) between 2011 and 2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155490/
https://www.ncbi.nlm.nih.gov/pubmed/37138364
http://dx.doi.org/10.1186/s13098-023-01069-y
work_keys_str_mv AT rodriguezescobedoraul reclassificationoftype2diabetestotype1diabetesinasturiasspainbetween2011and2020
AT lambertcarmen reclassificationoftype2diabetestotype1diabetesinasturiasspainbetween2011and2020
AT moralessanchezpaula reclassificationoftype2diabetestotype1diabetesinasturiasspainbetween2011and2020
AT delgadoalvarezelias reclassificationoftype2diabetestotype1diabetesinasturiasspainbetween2011and2020
AT menendeztorreedelmiro reclassificationoftype2diabetestotype1diabetesinasturiasspainbetween2011and2020